Re: Control (new / unique / detailed perspective)


"Antares 531" <gordonlrDELETE@xxxxxxxxxx> wrote...

On Tue, 13 Dec 2011 19:42:30 -0600, "Pro-Humanist FREELOVER"
<prohuman@xxxxxxxxxxxx> wrote:


- - -

[skipped pillpopper's avoidance of dealing
with whatever glucose anomaly he has,
including his avoidance of acknowledging
which glucose anomaly he has, along with
his incessant inappropriate inaccurate guilt-
tripping tripe he tosses ad infinitum]

Control?
http://prohuman.net/control.htm

The following offers hope, for those with
Insulinitis,

Have an insulinectomy. A tonsillectomy works very well for
tonsillitis. An appendectomy works very well for appendicitis, etc.

In Insulinitis, the insulin-producing cells of
the islets of Langerhans, in the overwhelming
majority of cases, were attacked/killed due
to Insulitis (an existing word), and as those
cells are required for the release of insulin,
there are efforts underway to restore them,
the article you omitted (without noting your
omission) being a recent and promising 'cure'
or 'much-improved treatment' (perspectives
differ on what it takes to call something a
'cure' or 'near-cure' or 'much-improved treat-
ment').

In a small minority of cases, some other
causality (like pancreas cancer or surgery
to treat pancreas cancer or a serious
bodily wound as can occur in war) causes
loss of all insulin production, and in those
cases, the Insulinitis word applies, as the
2nd part of the "itis" suffix definition is
potent in conveying the following, for
everyone with Insulinitis, regardless of
causality.

The obsession that everyone with Insulinitis
has with insulin, that, too, may be relieved
via the article you omitted (without noting
your omission). See the post you replied
to for details.

As for names, while reading the material
in the original post in this thread, I ran
across the following of import:
http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/basics/hormones.html

Excerpt:

....

Finally, a comment on the names given hormones
and what some have called the tyranny of terminology.
Hormones are inevitably named shortly after their
discovery, when understanding is necessarily rudimentary.
They are often named for the first physiologic effect
observed or for their major site of synthesis.

As knowledge and understanding of the hormone grow,
the original name often appears inappropriate or too
restrictive, but it has become entrenched in the liter-
ature and is rarely changed. In other situations, a
single hormone will be referred to by more than one
name. The problem is that the names given to hormones
often end up being either confusing or misleading. The
solution is to view names as identifiers rather than strict
guidelines to source or function.

....

- - - end excerpt - - -

Since my name change ideas are applying to a set of
conditions, also referred to as a disease or as a set
of disparate diseases, I'll translate the above to a form
applicable to my effort:

A comment on the names given diseases and what
some have called the tyranny of terminology. Diseases
are inevitably named shortly after their discovery,
when understanding is necessarily rudimentary. In
the case of diabetes, the name was based on the
excessive urination present in everyone with the
condition, close to 2,000 years ago when the name
originated.

As knowledge and understanding of the disease grew,
dramatically, in the 1920s and 1930s, the differences
in types of diabetes became better understood. As
genetic knowledge expanded later in the 20th century,
an entirely new type of glucose anomaly was discovered,
and given the diabetes leveraged name, Mature Onset
Diabetes of the Young. Yet, still, in the media, many
fail to recognize that distinct and different type, and
many still cling to the ancient urination-leveraged word
for all High Glucose Conditions, regardless of type.

The diabetes word, deeply entrenched in the literature,
appears inappropriate and far removed from the actual
nature of the disparate glucose anomalies. Hence, to
clear up the confusion and misinformation which oft-
times occurs when the diabetes word is used to des-
cribe a specific type of High Glucose Condition, but
the type is not mentioned, new words are desperately
needed.

The problem is that to-date, the names that have
been widespread for every one of the High Glucose
Conditions is leveraged off of an ancient deeply
entrenched core word, diabetes, which is both
confusing and misleading when any of the dispar-
ate types of High Glucose Conditions is described
as if it's the same as the other types (which occurs
when the diabetes core word is used without clari-
fier).

New names, that's the solution, especially for the
gaggle of confusing misleading insulting anachron-
istic ancient inappropriate diabetes / diabetic core
words and associated clarifier phrases. All of that,
long past time we bury it in the ancient past where
it belongs, and replace it with new, distinctly iden-
tifiable, non-confusing, non-misleading, accurate
and estimable terms -- see my sig for details.

Here's the remainder of the post you replied to,
which you omitted without noting your omission:

....

The following offers hope, for those with
Insulinitis, the primary focus of the article,
but also, for those with Diminosis who cur-
rently use insulin injections as part of their
treatment, and for those with Cellosis who
currently use insulin injections (estimated
to be about 25% of persons with Cellosis
in America) along with oral meds / exer-
cise / diet and/or weight loss to deal with
that condition:

- - -
December 13, 2011

JDRF to Support ViaCyte's Development
of Innovative Encapsulated Beta Cell
Replacement Therapy

at prnewswire.com
http://tinyurl.com/encapsulated-beta-cell-insulin
- - -

Excerpts [with insert, not part of original article,
included in brackets]:

JDRF announced today its support of a pioneering ...
research program that is developing a first-of-its-kind
cell therapy ...

The therapy is a combination product that packages
immature cells made from human embryonic stem cells
(hESCs) that over time develop into mature pancreatic
hormone producing cells (pro-islet) including insulin-
producing cells. The research is an important step
toward producing an unlimited source of insulin-pro-
ducing cells that could serve as replacements for
those destroyed ...

.... funded by JDRF, the largest charitable funder of
T1D [Insulinitis] research in the world, the California
Institute for Regenerative Medicine (CIRM), and ViaCyte,
a San Diego, California-based biotechnology company ...

.... ViaCyte's program will provide a replenishable supply
of functional insulin-producing cells. Furthermore, pack-
aging the cells in a device ("encapsulation") creates a
physical barrier around the cells and has the potential to
protect the transplanted cells from immune rejection, and
may eliminate the need for chronic immunosuppressive
drugs.

The ultimate goal of this partnership is to help patients
with T1D [Insulinitis] restore their ability to regulate
blood glucose, thereby reducing or eliminating the need
for constant self-management and administration of
insulin.

"Encapsulation research is one of JDRF's priorities because
of the profound possibilities it holds for many avenues of
research for type 1 diabetes [Insulinitis]," said Julia Green-
stein, JDRF's assistant vice president for Cure therapies.
"We're excited about partnering with ViaCyte to explore
the use of encapsulated stem cell-based replacement.

This type of innovative therapy could revolutionize the
way people live with type 1 diabetes [Insulinitis], and
may also reduce the risk of dangerous complications
that often result from extreme high and low blood
sugars."

- - - end excerpts - - -

- - - - - - - - - - - - - - - - - - - - - - - - - -

Viacyte
http://www.viacyte.com/

Viacyte Technologies Overview
http://www.viacyte.com/tech/

Viacyte Stem Cell Engineering
http://www.viacyte.com/tech/engineering.html

Viacyte Cell Encapsulation
http://www.viacyte.com/tech/encapsulation.html

Viacyte Clinical Application
http://www.viacyte.com/trials/index.html

Excerpts [with inserts, not part of original article,
included in brackets]:

As beta cell loss is the primary pathogenesis of
insulin-dependent diabetes [Insulinitis], the disease
is a great candidate for cell replacement therapy.
To this end, ViaCyte's lead cell therapy product,
called Pro-IsletT, is being developed to provide
replacement beta cells ...

Pro-IsletT cells for medical or clinical use are
expected to provide the same types of benefits
as intensive insulin therapy but without the
trouble of frequent blood sugar monitoring and
insulin injections, and without the risk of unsafe
hypoglycemic events.

Because Pro-IsletT is comprised of human cells
it uses natural biological mechanisms to respond
to blood sugar [glucose] levels.

Indeed, not only blood sugar [glucose] is moni-
tored and regulated by the pancreatic Islets of
Langerhans [in people without Insulinitis], but
numerous other activities in the blood, reflecting
the body's overall physiological state, are also
relevant, and Pro-IsletT will respond to the full
array of inputs as well.

Likewise, the response of Pro-IsletT is not just
that of releasing insulin, but also includes the
full repertoire of beta cell functions that are
lost in [totally or near-totally in persons with
Insulinitis, in varying degrees with lessened
but continuing insulin production in persons
with Diminosis or Cellosis].

As Pro-IsletT will employ physiologically rele-
vant detection, and response to blood chemis-
tries on a continuous basis, as compared to
pharmaceutical insulin, it may well represent
a quantum advance in medical treatment [for
the conditions previously mentioned, although
of note, it does not address the insulin resistance
which underlies the causality of the high glucose
problem present in those with Cellosis, so it's
unclear the extent to which alterations in other
treatments will be required to mate to improve-
ments in insulin release in those with Cellosis].

- - - end excerpts - - -

- - - - - - - - - - - - - - - - - - - - - - -

- - -
Pro-Humanist FREELOVER
C.ure I.nsulinitis A.ssociation
http://prohuman.net/cureinsulinitisassociation.htm
- - -


.

Relevant Pages

  • Re: Complacency
    ... test their blood glucose once daily. ... you are on oral medication, unlike insulin, your blood glucose will ... remain at similar fasting glucose levels through out the day. ... The study, which was presented here at the 17th International Diabetes Federation Congress, provides further validation of 2h-BG as an independent risk factor for death from heart disease. ...
    (alt.support.diabetes)
  • Re: A test for Glass318
    ... glucose in such a way that energy is released in the form of ATP, ... aminoacids and free fatty acids. ... g) When Insulin is called on, it goes around telling your cells to ...
    (alt.support.diabetes)
  • Popular Science Archives on High Glucose Conditions -- 1872 to 1999 (12 articles)
    ... kidneys and diabetes ... ... Insulin -- A Miracle of Science ... insulin does when injected into persons suffering from ... by the body's destruction of pancreatic cells that pro- ...
    (alt.support.diabetes)
  • Popular Science Archives on High Glucose Conditions -- 1872 to 1999 (12 articles)
    ... kidneys and diabetes ... ... Insulin -- A Miracle of Science ... insulin does when injected into persons suffering from ... by the body's destruction of pancreatic cells that pro- ...
    (misc.health.diabetes)
  • Re: A test for Glass318
    ... glucose in such a way that energy is released in the form of ATP, ... aminoacids and free fatty acids. ... e) Insulin is a hormone that your body calls whenever your ... g) When Insulin is called on, it goes around telling your cells to ...
    (alt.support.diabetes)